To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

A randomised, open-label,… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

A randomised, open-label, crossover study of the dopamine agonist, pramipexole, in patients with sleep bruxism

Journal article
Authors Birgitta Johansson Cahlin
Jan A Hedner
Lars Dahlström
Published in Journal of Sleep Research
Volume 26
Issue 1
Pages 64-72
ISSN 0962-1105
Publication year 2017
Published at Institute of Odontology
Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Pages 64-72
Language en
Links dx.doi.org/10.1111/jsr.12440
Keywords dopaminergic medication, electromyography, polysomnography, restless legs syndrome, restless legs syndrome, temporomandibular disorders, diagnostic-criteria, time, polysomnography, population, prevalence, management, validity, arousals, Neurosciences & Neurology
Subject categories Dentistry

Abstract

Sleep bruxism bears several similarities to restless legs syndrome, and a link to changes in central dopamine activity has been considered in both conditions. The dopamine agonist pramipexole is currently indicated for the symptomatic treatment of restless legs. The effect of pramipexole on sleep bruxism was investigated in subjects with 'probable bruxism' recruited at the Orofacial Pain Clinic. Thirteen patients underwent polysomnographic recordings, including bilateral masseter electromyographic activity. Following habituation to the recording equipment, a baseline registration was used to confirm bruxism [total episodes per hour, mean 11.3 (6.3)]. Following randomisation, subjects received no treatment or pramipexole titrated from 0.09 to 0.54 mg, o. d., for 3 weeks according to a crossover procedure. A polysomnographic- electromyographic registration was performed at the end of each period. Pramipexole was associated with more frequent awakenings and a reduction in rapid eye movement sleep (both P = 0.02). Sleep apnea decreased marginally after pramipexole (apnea- hypopnea index 17.1 compared with control 21.5, P = 0.05). The number of bruxism episodes, phasic, tonic and mixed per hour, remained unchanged after pramipexole [total episodes per hour 12.7 (8.5) and 9.8 (5.2) during pramipexole and control conditions, respectively]. It is concluded, from this pilot study, that sleep bruxism is not affected by the dopaminergic agent, pramipexole.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?